Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Clinical Pharmacology and Therapeutics|January 27, 2026
Longitudinal Tumor Size and Survival Modeling for Exposure-Response Analysis of Drugs with Frequent Dose Reductions: Dose Justification of Abemaciclib in Patients with Metastatic Breast CancerEmmanuel Chigutsa, Sonya C Chapman, P Kellie Turner
CPT: Pharmacometrics & Systems Pharmacology|October 30, 2025
Application of Physiologically-Based Pharmacokinetic Modeling to Support Drug Labeling: Prediction of CYP3A4-Mediated Pirtobrutinib-Drug InteractionsDan-Dan Tian, Stephen D Hall, Sonya C Chapman, et al.
European Journal of Pharmaceutical Sciences : Official Journal of the European Federation for Pharmaceutical Sciences|March 5, 2021
Investigating the impact of target lesion selection on drug effect evaluation and tumour growth rate determination using tumour growth inhibition models: Example of malignant pleural mesothelioma patients treated with cisplatin alone or in combination with pemetrexedAurélie Lombard, Hitesh Mistry, Sonya C Chapman, et al.
Cancer Chemotherapy and Pharmacology|March 15, 2020
Impact of tumour size measurement inter-operator variability on model-based drug effect evaluationAurélie Lombard, Hitesh Mistry, Sonya C Chapman, et al.
Drug Metabolism and Disposition: the Biological Fate of Chemicals|June 26, 2020
Abemaciclib Does Not Have a Clinically Meaningful Effect on Pharmacokinetics of CYP1A2, CYP2C9, CYP2D6, and CYP3A4 Substrates in Patients with CancerP Kellie Turner, Stephen D Hall, Sonya C Chapman, et al.
Targeted Oncology|January 25, 2021
A Randomized Phase I Study of Abemaciclib in Chinese Patients with Advanced and/or Metastatic CancersJian Zhang, Nong Yang, Dongmei Ji, et al.
Frontiers in Oncology|March 27, 2025
Abemaciclib in combination with therapies for patients with metastatic breast cancer: a phase 1b studySara M Tolaney, Komal Jhaveri, Teresa Helsten, et al.
NPJ Breast Cancer|November 6, 2022
Abemaciclib in combination with pembrolizumab for HR+, HER2- metastatic breast cancer: Phase 1b studyHope S Rugo, Peter Kabos, J Thad Beck, et al.
Cancer Medicine|October 16, 2023
Efficacy and safety of abemaciclib alone and with PI3K/mTOR inhibitor LY3023414 or galunisertib versus chemotherapy in previously treated metastatic pancreatic adenocarcinoma: A randomized controlled trialE Gabriela Chiorean, Vincent Picozzi, Chung-Pin Li, et al.
Investigational New Drugs|February 24, 2021
LY3022855, an anti-colony stimulating factor-1 receptor (CSF-1R) monoclonal antibody, in patients with advanced solid tumors refractory to standard therapy: phase 1 dose-escalation trialAfshin Dowlati, R Donald Harvey, Richard D Carvajal, et al.
Pageof 3